RNAs that make a heart beat

Mitra, Mithun; Coller, Hilary A.

doi:10.21037/atm.2016.11.39

Cited by 5 publications

(5 citation statements)

References 57 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Co-transfection of luciferase-Kcnd2 and miR-223–3p suppressed luciferase activity. miR 223–3p also regulates KCND2 and cardiac action potential [ 22 , 23 ]. Furthermore, a decrease-of-I Na and an elevated I to could induce the ventricular cardiomyocytes in patients with BrS, causing proarrhythmic changes [ 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

Plasma MicroRNAs as noninvasive diagnostic biomarkers in patients with Brugada syndrome

et al. 2022

View full text Add to dashboard Cite

Background Brugada syndrome (BrS) can be diagnosed by a type 1 BrS tracing in a 12-lead electrocardiogram (ECG). However, there are daily variations in the ECGs of BrS patients, which presents a challenge when diagnosing BrS. Although many susceptibility genes have been identified, the SCN5A gene is reportedly the main causative gene of BrS. However, most patients do not have an evidence of genetic predisposition to develop BrS. In addition, the diagnosis and risk stratification for ventricular fibrillation (VF) in patients with BrS presents some problems. Meanwhile, circulating micro RNAs (miRNAs) have drawn increased attention as potential biomarkers of various diseases. We hypothesize that circulating miRNAs may be potential diagnostic biomarkers for BrS. Methods We enrolled 70 Japanese BrS patients and 34 controls for the screening cohort. A total of 2,555 miRNA sequences were detected using the 3D-Gene miRNAs labeling kit and 3D-Gene Human miRNAs Oligo Chip. We compared the expression of the miRNAs between the BrS patients and the controls. We validated whether the miRNA were significantly up- or downregulated in the screening cohort using RT-PCR. We also enrolled 72 Japanese BrS patients and 56 controls to replicate these miRNAs. Results Eight miRNAs (hsa-miR-223-3p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-4485-5p, hsa-miR-550a-5p, hsa-miR-423-3p, hsa-miR-23a-3p, and hsa-miR-30d-5p) were downregulated, and one miRNA (hsa-miR-873-3p) was upregulated by more than 3-fold in BrS patients. The multivariate logistic regression analysis determined that hsa-miR-423-3p, hsa-miR-223-3p, and hsa-miR-23a-3p were independently associated with BrS (P < 0.0001). The AUC based on cross validation was 0.871 with a sensitivity and specificity of 83.5% and 81.1%, respectively. Conclusions The plasma miRNAs are potential noninvasive biomarkers of BrS, and the constructed logistic model was useful for discriminating BrS.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma MicroRNAs as noninvasive diagnostic biomarkers in patients with Brugada syndrome

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These cellular mechanisms could be responsible for the arrhythmogenic potential of miR-1. Consistent with this hypothesis, the introduction of miR-1 worsened arrhythmias, while suppression through antisense inhibitors reduced arrhythmias in rats undergoing an MI [ 33 ]. Moreover, propranolol, a β-blocker used as an antiarrhythmic agent, can downregulate miR-1 expression and thus improve cardiac conduction [ 34 ].…”

Section: Introductionmentioning

confidence: 86%

“…miR-1 represses the gap junction protein alpha 1 (GJA1), which encodes the connexin-43 gap junction channel protein, thus slowing down the cardiac conduction in the setting of an MI [ 32 ]. Other targets of miR-1 include the notch ligand delta, the Rho GTPase Cdc42 , Iroquois homeobox domain 5 ( Irx5 ), and Shal-related family member 2 ( KCND2 ) [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

“…miRNAs and inhibitors of miRNAs do not affect the existing proteins but rather alter the levels of mRNA and their translation. Therefore, it would be necessary to understand the pharmacokinetics of any proposed miRNA therapy [ 33 ]. Studies are also required to develop stable anti-miRNAs that can achieve therapeutic efficacy in the heart and to better prevent any off-target effects [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, it would be necessary to understand the pharmacokinetics of any proposed miRNA therapy [ 33 ]. Studies are also required to develop stable anti-miRNAs that can achieve therapeutic efficacy in the heart and to better prevent any off-target effects [ 33 ]. Further, the overexpression of any miRNAs for therapeutic purposes requires viral approaches, which would pose a potential challenge for any translational studies in humans [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Brief Review on the Biology and Effects of Cellular and Circulating microRNAs on Cardiac Remodeling after Infarction

Parikh

Pierce

2021

IJMS

View full text Add to dashboard Cite

Despite advances in diagnostic, prognostic, and treatment modalities, myocardial infarction (MI) remains a leading cause of morbidity and mortality. Impaired cellular signaling after an MI causes maladaptive changes resulting in cardiac remodeling. MicroRNAs (miRNAs/miR) along with other molecular components have been investigated for their involvement in cellular signaling in the pathogenesis of various cardiac conditions like MI. miRNAs are small non-coding RNAs that negatively regulate gene expression. They bind to complementary mRNAs and regulate the rate of protein synthesis by altering the stability of their targeted mRNAs. A single miRNA can modulate several cellular signaling pathways by targeting hundreds of mRNAs. This review focuses on the biogenesis and beneficial effects of cellular and circulating (exosomal) miRNAs on cardiac remodeling after an MI. Particularly, miR-1, -133, 135, and -29 that play an essential role in cardiac remodeling after an MI are described in detail. The limitations that will need to be addressed in the future for the further development of miRNA-based therapeutics for cardiovascular conditions will also be discussed.

show abstract

Post translational modifications of connexin 43 in ventricular arrhythmias after myocardial infarction

Yang,

Zhang,

Liu

et al. 2024

Mol Biol Rep

View full text Add to dashboard Cite

RNAs that make a heart beat

Cited by 5 publications

References 57 publications

Plasma MicroRNAs as noninvasive diagnostic biomarkers in patients with Brugada syndrome

Plasma MicroRNAs as noninvasive diagnostic biomarkers in patients with Brugada syndrome

A Brief Review on the Biology and Effects of Cellular and Circulating microRNAs on Cardiac Remodeling after Infarction

Post translational modifications of connexin 43 in ventricular arrhythmias after myocardial infarction

Contact Info

Product

Resources

About